<table>
<thead>
<tr>
<th>Document Type</th>
<th>Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index Number</td>
<td>Registry 102</td>
</tr>
<tr>
<td>Version Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Title</td>
<td>DRAFT_Lymphomas</td>
</tr>
<tr>
<td>Author</td>
<td>Annelot van Amerongen</td>
</tr>
<tr>
<td>Authorised By</td>
<td>N/A</td>
</tr>
<tr>
<td>Authorised On</td>
<td>N/A</td>
</tr>
<tr>
<td>Release Date:</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested. Consult the manual for further information.

Date of diagnosis: _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Classification:

- [ ] B-cell non-Hodgkin lymphoma (NHL)
- [ ] T-cell non-Hodgkin lymphoma (NHL)
- [ ] Hodgkin lymphoma
- [ ] Immunodeficiency-associated lymphoproliferative disorder (incl. PTLD)
**LYMPHOMAS**  
**B-Cell Non-Hodgkin Lymphomas (NHL)**

### DISEASE

#### Sub-Classification: Mature B-cell neoplasms

- [ ] Splenic marginal zone lymphoma
- [ ] Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)
- [ ] Nodal marginal zone lymphoma
- [ ] Lymphoplasmacytic lymphoma (LPL)
  - [ ] Waldenstrom macroglobulinaemia (LPL with monoclonal IgM)
- [ ] Follicular lymphoma
  - **Grading:**
    - [ ] Grade I
    - [ ] Grade II
    - [ ] Grade IIIa
    - [ ] Grade IIIb
    - [ ] Not evaluated
- [ ] Primary cutaneous follicle centre lymphoma
- [ ] Mantle cell lymphoma
  - **Grading:**
    - [ ] Indolent
    - [ ] Classical
    - [ ] Pleomorphic
    - [ ] Blastoid
    - [ ] Not evaluated
- [ ] T-cell/histiocyte-rich large B cell lymphoma
- [ ] Primary DBCL of the CNS
- [ ] Primary cutaneous DLBCL, leg type
- [ ] EBV positive DBCL of the elderly
- [ ] Germinal centre B-cell type (GCB) DLBCL
- [ ] Activated B-cell type (ABC or non-GCB) DLBCL
- [ ] DLBCL associated with chronic inflammation
- [ ] Lymphomatoid granulomatosis
- [ ] Primary mediastinal (thymic) large B-cell lymphoma
- [ ] Intravascular large B-cell lymphoma
- [ ] ALK-positive large B-cell lymphoma
- [ ] Plasmablastic lymphoma
- [ ] HHV8-positive DLBCL,NOS
- [ ] Diffuse large B-cell lymphoma (DLBCL), (NOS)
- [ ] Primary effusion lymphoma (PEL)
- [ ] Burkitt lymphoma (BL)
- [ ] High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
- [ ] B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (Intermediate DLBCL/BL)
- [ ] B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (Gray zone lymphoma)
- [ ] Other B-cell non-Hodgkin lymphoma: specify

**KI-67:** __ __ % positive  
*(proliferation index)*

- [ ] Not evaluated
DISEASE continued

High-grade transformation of indolent B-cell lymphoma?

☐ No
☐ Yes  (If not reported yet, complete respective non-indication diagnosis form in addition to the current form)
☐ Unknown

Parameters for international prognostic indices:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDH levels elevated:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ann Arbor staging:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG performance status:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 1 extranodal site involved:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 4 nodal sites involved:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin &lt; 120g/L:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White Blood Cell count:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CHROMOSOME ANALYSIS

Please complete chromosome analysis, molecular marker analysis and immunophenotyping sections only for patients with the following types of B-cell NHL:
- Mantle cell lymphoma
- Waldenstrom macroglobulinaemia (LPL with monoclonal IgM)
- Burkitt lymphoma or Intermediate DLBCL/BL

Chromosome analysis done before treatment (all methods including FISH):

☐ Not done or failed
☐ Yes, abnormal results: number of abnormalities present:_____
☐ Yes, normal results
☐ Unknown

Date of chromosome analysis (if tested): _ _ / _ _ / _ _ (YYYY/MM/DD)

Indicate below whether the abnormalities were absent, present or not evaluated. according to the type of lymphoma diagnosed.
### MOLECULAR MARKER ANALYSIS

Please complete chromosome analysis, molecular marker analysis and immunophenotyping sections only for patients with the following types of B-cell NHL:
- Mantle cell lymphoma
- Waldenstrom macroglobulinaemia (LPL with monoclonal IgM)
- Burkitt lymphoma (BL) or Intermediate DLBCL/BL

**Molecular marker analysis done before treatment:**

- [ ] No
- [ ] Yes
- [ ] Unknown

**Date of molecular marker analysis (if tested):**    _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Indicate below whether the markers were absent, present or not evaluated, according to the type of lymphoma diagnosed.

<table>
<thead>
<tr>
<th></th>
<th>TP53 mutation</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mantle cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkitt lymphoma or Intermediate DLBCL/BL</td>
<td>myc rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Intermediate DLBCL/BL</td>
<td>BCL2 rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td></td>
<td>BCL6 rearrangement</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>All B-cell lymphomas</td>
<td>Other molecular markers; specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
</tbody>
</table>

### IMMUNOPHENOTYPING

Please complete chromosome analysis, molecular marker analysis and immunophenotyping sections only for patients with the following types of B-cell NHL:
- Mantle cell lymphoma
- Waldenstrom macroglobulinaemia (LPL with monoclonal IgM)
- Burkitt lymphoma (BL) or Intermediate DLBCL/BL

**Immunophenotyping done before treatment:**

- [ ] No
- [ ] Yes
- [ ] Unknown

**Date of immunophenotyping (if tested):**    _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Indicate below whether the immunophenotypes were absent, present or not evaluated, according to the type of lymphoma diagnosed.

<table>
<thead>
<tr>
<th></th>
<th>SOX 11</th>
<th>Absent</th>
<th>Present</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mantle cell lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkitt lymphoma or Intermediate DLBCL/BL</td>
<td>MYC</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>Intermediate DLBCL/BL</td>
<td>BCL2/IgH</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td></td>
<td>BCL6</td>
<td>Absent</td>
<td>Present</td>
<td>Not evaluated</td>
</tr>
<tr>
<td>All B-cell lymphomas</td>
<td>Other immunophenotype; specify:</td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
</tbody>
</table>
### Lymphomas

#### T-Cell Non-Hodgkin Lymphomas (NHL)

**Sub-Classification:** Mature T-cell & NK-cell Neoplasms

- [ ] T-cell large granular lymphocytic leukaemia
- [ ] Aggressive NK-cell leukaemia
- [ ] Systemic EBV positive T-cell lymphoproliferative disease of childhood
- [ ] Hydroa vacciniforme-like lymphoma
- [ ] Adult T-cell leukaemia/lymphoma
- [ ] Extranodal NK/T-cell lymphoma, nasal type
- [ ] Enteropathy-associated T-cell lymphoma
- [ ] Monomorphic epithelioid intestinal T-cell lymphoma
- [ ] Hepatosplenic T-cell lymphoma
- [ ] Subcutaneous panniculitis-like T-cell lymphoma
- [ ] Mycosis fungoides (MF)
- [ ] Sézary syndrome
- [ ] Lymphomatoid papulosis
- [ ] Primary cutaneous anaplastic large cell lymphoma
- [ ] Primary cutaneous gamma-delta T-cell lymphoma
- [ ] Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma
- [ ] Primary cutaneous CD4 positive small/medium T-cell lymphoma
- [ ] Peripheral T-cell lymphoma NOS (PTCL)
- [ ] Angioimmunoblastic T-cell lymphoma
- [ ] Anaplastic large-cell lymphoma (ALCL), ALK-positive
- [ ] Anaplastic large-cell lymphoma (ALCL), ALK-negative
- [ ] Other T-cell non-Hodgkin lymphoma; specify: ________________________
LYMPHOMAS
Hodgkin Lymphomas

DISEASE

**Sub-Classification:** Hodgkin Lymphomas

- [ ] Nodular lymphocyte predominant
- [ ] Classical predominant; lymphocyte-rich
- [ ] Classical predominant; nodular sclerosis
- [ ] Classical predominant; mixed cellularity
- [ ] Classical predominant; lymphocyte-depleted
- [ ] Classical predominant; NOS
- [ ] Other Hodgkin lymphoma; specify: __________________________
## Lymphomas

Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)

### Disease Sub-Classification:

- Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)
  - Lymphoproliferative disease associated with primary immune disorder
  - Lymphoma associated with HIV infection
  - Post-transplant lymphoproliferative disorder (PTLD)
    - Non-destructive PTLD
      - Plasmacytic hyperplasia PTLD
      - Infectious mononucleosis PTLD
      - Florid follicular hyperplasia PTLD
    - Polymorphic PTLD
    - Monomorphic PTLD
      - B-cell type
      - T/NK-cell type
    - Classical Hodgkin lymphoma PTLD
  - Other immunodeficiency-associated lymphoproliferative disorder

### Did the disease result from a previous solid organ transplant?

- No
- Yes:
  - Date of transplant: __ __ / __ / __ (YYYY/MM/DD)
  - Type of transplant:
    - Renal
    - Cardiac
    - Pulmonary
    - Other; specify: __________________________

- Unknown
## LYMPHOMAS

### PREVIOUS THERAPIES BEFORE HCT/CT

<table>
<thead>
<tr>
<th>Line of treatment</th>
<th>Regimen used*</th>
<th>Treatment start date (YYYY/MM/DD)</th>
<th>Response to this line of treatment</th>
<th>Response assessment date (YYYY/MM/DD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td><strong>/</strong>/__</td>
<td>□ Complete remission (CR)</td>
<td><strong>/</strong>/__</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Stable disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Chemorefractory relapse or progression incl. primary refractory disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Unknown</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td><strong>/</strong>/__</td>
<td>□ Complete remission (CR)</td>
<td><strong>/</strong>/__</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Stable disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Chemorefractory relapse or progression incl. primary refractory disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Unknown</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td><strong>/</strong>/__</td>
<td>□ Complete remission (CR)</td>
<td><strong>/</strong>/__</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Stable disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Chemorefractory relapse or progression incl. primary refractory disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Unknown</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td><strong>/</strong>/__</td>
<td>□ Complete remission (CR)</td>
<td><strong>/</strong>/__</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Stable disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Chemorefractory relapse or progression incl. primary refractory disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□ Unknown</td>
<td></td>
</tr>
</tbody>
</table>

*Copy and fill-in this section as many times as necessary*

*Please consult the LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS on the EBMT website for drugs/regimens names*